Samchundang Pharmaceutical Completes Reorganization of Global Patent Rights Structure for "S-PASS"
"Change of PCT Applicant and Reorganization of Patent Rights in Taiwan"
"Unification of IP System for Global Commercialization and Licensing Negotiations"
Samchundang Pharmaceutical announced on May 21 that it has completed the process of changing the applicant for the PCT (Patent Cooperation Treaty) international patent application related to its oral drug delivery platform "S-PASS," as well as reorganizing the patent rights structure in Taiwan.
According to the company, these procedures were measures taken to expand the global business of the S-PASS platform and to unify its intellectual property (IP) management system.
S-PASS is an oral drug delivery platform technology currently being developed by Samchundang Pharmaceutical. The goal is to convert existing injection-based biopharmaceuticals into oral formulations.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If a Samsung Electronics Employee with a 100 Million Won Salary Receives a 600 Million Won Performance Bonus, Taxes Total 247.19 Million Won
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- Park Minshik Shaves Head: "I Will End Han Donghoon's Predatory and Parasitic Politics"... Ongoing Calls for Conservative Consolidation in Busan Buk-gu Gap within PPP
A representative from Samchundang Pharmaceutical stated, "This reorganization of the rights structure is part of the process of systematizing our IP portfolio in line with our global commercialization and licensing strategy," adding, "Going forward, we plan to promote research and development as well as global commercialization based on the S-PASS platform in a step-by-step manner."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
